Viracta Therapeutics, Inc.
DelistedCIK 1061027fmd_0X254TXMPXAEQ7X73468XJC2K0Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2009 to Sep 30, 2024, 59 periods
| Line item | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 6 | 3 | 3 | 1 | 0 | 2 | 0 | – | – | – |
| Research and development | 28 | 24 | 23 | 22 | 15 | 9 | 13 | 24 | 26 | 33 |
| Total operating expenses | 51 | 42 | 39 | 35 | 26 | 12 | 19 | 128 | 51 | 51 |
| Operating income | (45) | (39) | (36) | (34) | (26) | (23) | (19) | (114) | (51) | (51) |
| Interest expense | 2 | 1 | 2 | 1 | 1 | 0 | 0 | 0 | 1 | 4 |
| Interest and investment income | – | – | – | – | – | – | – | – | 1 | 3 |
| Other non-operating income (expense) | 4 | 4 | 0 | 0 | 0 | (2) | (0) | (0) | 1 | (0) |
| Income before taxes | (43) | (37) | (38) | (35) | (27) | (23) | (22) | – | – | – |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | (43) | (37) | (38) | (35) | (27) | (23) | (22) | – | – | – |
| Net income | (43) | (37) | (38) | (35) | (27) | (14) | (19) | (115) | (49) | (51) |
| Net income to common shareholders | (43) | (37) | (38) | (35) | – | – | – | – | – | – |